| editorial | Q871232 |
| scholarly article | Q13442814 |
| P2093 | author name string | C Legendre | |
| G Canaud | |||
| F Terzi | |||
| P2860 | cites work | The pathogenesis of the antiphospholipid syndrome | Q34332601 |
| Endothelial cell activation by antiphospholipid antibodies is modulated by Kruppel-like transcription factors | Q35067429 | ||
| Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: What is the appropriate serum level? | Q36968695 | ||
| Pathogenesis of antiphospholipid syndrome: understanding the antibodies | Q37873720 | ||
| Influence of endothelial cells on vascular smooth muscle cells phenotype after irradiation: implication in radiation-induced vascular damages. | Q41345639 | ||
| Influence of endothelium on cultured vascular smooth muscle cell proliferation | Q42484963 | ||
| Phosphorylated S6 ribosomal protein: a novel biomarker of antibody-mediated rejection in heart allografts. | Q44630596 | ||
| Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome. | Q45034886 | ||
| Neointimal and tubulointerstitial infiltration by recipient mesenchymal cells in chronic renal-allograft rejection. | Q46038626 | ||
| Plasma membrane stress induces relocalization of Slm proteins and activation of TORC2 to promote sphingolipid synthesis. | Q54517310 | ||
| Inhibition of the mTORC pathway in the antiphospholipid syndrome. | Q55072769 | ||
| Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity | Q24598427 | ||
| AKT/PKB signaling: navigating downstream | Q24657857 | ||
| Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB | Q28306356 | ||
| The pathogenesis of atherosclerosis: a perspective for the 1990s | Q29547827 | ||
| A novel pathway for human endothelial cell activation by antiphospholipid/anti-β2 glycoprotein I antibodies | Q30422807 | ||
| Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes | Q33408360 | ||
| Donor MHC and adhesion molecules in transplant arteriosclerosis | Q33842691 | ||
| Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients | Q33968031 | ||
| Local medial microenvironment directs phenotypic modulation of smooth muscle cells after experimental renal transplantation. | Q34197007 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 227-230 | |
| P577 | publication date | 2015-01-27 | |
| P1433 | published in | Lupus | Q6704846 |
| P1476 | title | AKT/mTORC pathway in antiphospholipid-related vasculopathy: a new player in the game. | |
| P478 | volume | 24 |
| Q94940476 | Antiphospholipid Syndrome |
| Q47662342 | Antiphospholipid antibody-induced cellular responses depend on epitope specificity : implications for treatment of antiphospholipid syndrome |
| Q38410376 | Antiphospholipid syndrome: an update |
| Q47998109 | Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances |
| Q52654857 | Update on Antiphospholipid Syndrome: Ten Topics in 2017. |
Search more.